About this episode
A quiet revolution is underway in Indian oncology. Chinese-origin cancer drugs, brought to India through a growing number of pharma partnerships, are dramatically cutting the cost of immunotherapy — making treatment accessible to patients who previously had no options. Doctors are prescribing them, patients are responding well, and Indian companies — from Glenmark to Dr Reddy’s to Intas — are signing billion-dollar deals to expand access further. Western immunotherapy can cost up to five lakh rupees per session. Chinese-origin alternatives are bringing that down to fifty thousand. This episode explores how the India-China pharma axis is reshaping who gets treated, and how.
See omnystudio.com/listener for privacy information.
Get every episode summarized
Each time The Morning Brief publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Morning Brief
J.P.Morgan’s Anu Aiyengar on Mega Deals, AI’s Banking Reset and the India Bet
The Morning Brief
ET Deep Dive: When Development Turns Disaster
The Morning Brief
Subrata Mitra on India’s VC Reset, the AI Capital Race and What Comes Next
The Morning Brief
HDFC Bank’s CEO Hunt
The Morning Brief